Maybe it's the scientist in me, but I'm a pipeline kind of guy. Having multiple shots on goal from a single investment has seemed practical, perhaps even necessary.
But I'm warming to the idea of one-drug wonders, especially companies that have a clinical program in mid- or late-stage development and are on the verge of their first big hit. What the companies lack in safety, they make up in some special qualities.
Survival of the smallest
Cash burn rates have always been important to development-stage drugmakers, but the bear market, which has eliminated secondary offerings as an easy way to get more cash, has made it essential for investors to focus on how much cash a company is spending. Gone are the days when "if you build it they will come" was a legitimate investment thesis.
Simply put, the fewer drug programs a company has, the less cash the company will burn. Quite a few companies -- Anadys Pharmaceuticals, Dyax, and Replidyne, just to name a few -- have reassessed their pipeline and cut programs recently in order to try and extend their runway.
Bringing its A-game and leaving the second-best ideas on the back burner until the company has revenue coming in is a prudent use of cash in the current economic environment.
Looking good
Maybe the best benefit to investing in focused drug companies is the increased likelihood that the company will be acquired at a premium. Focused drug companies are attractive because the suitor can get exactly what it wants without a lot of extra baggage. And with fewer moving parts, it's easier for pharmaceutical companies to value their targets.
Company being Acquired |
Suitor |
Premium* |
---|---|---|
Omrix Biopharmaceuticals |
Johnson & Johnson |
18% |
CV Therapeutics |
Gilead Sciences |
76% |
ImClone Systems |
Eli Lilly |
50% |
Cougar Biotechnology |
Johnson & Johnson |
16% |
*Based on price before first bid was announced.
The more focused drug developers also tend to have fewer messy partnerships. Companies with multiple partners, like Exelixis
While there's a higher potential for a buyout with focused companies, I wouldn't recommend buying solely because of it. There are no guarantees that a company will be taken out, and even if the company is purchased, there's no assurance that it will be bought above the price you paid. Omrix was a perfect fit for Johnson & Johnson -- the companies were partners and every analyst figured the two would eventually be wed -- but the 18% premium that Johnson & Johnson paid was still below where Omrix traded a year before.
Consider the potential for an acquisition as a fringe benefit, but make your decision based on fundamentals.
Buy two (or more), they're cheap
Companies aspiring to be the next Onyx Pharmaceuticals or Amylin Pharmaceuticals
The way to deal with that risk is simply to diversify and build your own biotech ETF. You can establish your own personal pipeline of drugs by buying multiple focused drugmakers. Not every drug will make it through clinical trials and past the Food and Drug Administration, but all you need is one home run to make up for multiple failures.
Worth a closer look
Given that, here are a couple that I like today:
Dendreon
Technically, AMAG Pharmaceuticals
As always, be a Foolish investor and look more deeply into these companies before investing. One-drug wonders can really boost a portfolio, but they can also crash and burn.